Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Mallinckrodt Plc Add to portfolio

NYA:MNK, Apr 23, 04:42 UTC

Latest NYA:MNK News

Filter your feed

Apply Filter

Friday, April 19


News

Report: Exploring Fundamental Drivers Behind Abercrombie & Fitch, VALE S.A, Mallinckrodt public limited company, Veritone, Tecnoglass, and Redhill Biopharma — New Horizons, Emerging Trends, and Upcoming Developments

MNK ANF

The new research reports from Capital Review, available for free download at the links above, examine Abercrombie & Fitch Company (NYSE:ANF), VALE S.A. (NYSE:VALE), Mallinckrodt public limited company (NYSE:MNK), Veritone, Inc. (NASDAQ:VERI), Tecnoglass Inc. (NASDAQ:TGLS), and Redhill Biopharma Ltd. (NASDAQ:RDHL) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. The estimated EPS forecast for the next fiscal year is $1.42 and is expected to report on March 4th, 2020. VALE S.A's Recent Financial Performance. For the three months ended September 30th, 2018 vs September 30th, 2017, VALE S.A reported revenue of $9,543.00MM vs $9,050.00MM (up 5.45%) and analysts estimated basic earnings per share $0.27 vs $0.43 (down 37.21%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, VALE S.A reported revenue of $36,575.00MM vs $33,967.00MM (up 7.68%) and analysts estimated basic earnings per share $1.32 vs $1.05 (up 25.71%).

Read Full Details

Topics:
  • Business
  • Financial

Thursday, April 18


News

Mallinckrodt Reports Top-Line Results from Proof-of-Concept Study of Nitric Oxide Gas in Ex-Vivo System of Human Lung Transplants

MNK

Matthew Hartwig, M.D., a lung transplant surgeon at Duke University and the study's Principal Investigator, said: "We are very excited about the preliminary results from this proof-of-concept study. We still have a lot of work to do, but in human lungs not suitable for clinical transplantation, the study showed an improvement in oxygenation and a longer duration of out-of-body perfusion time in lungs perfused with gNO, which are both important parts of a successful ex-vivo lung perfusion." "Mallinckrodt is focused on providing treatment options for underserved patients' needs, improving outcomes for those with severe and critical conditions. The company has more than 20 years of experience with, and investment in, nitric oxide as a signaling molecule," said Steven Romano, M.D., Executive Vice President and Chief Scientific Officer at Mallinckrodt. "We are pleased to see these encouraging preliminary, top-line data, and plan to publish the full data set at a future research meeting. This is important research in evaluating the therapy's potential use in lung transplantation as the company seeks to establish and grow its presence in a key therapeutic area." The study evaluated extended (modified) criteria bilateral donor lungs, not eligible for lung transplantation. A variety of diseases and conditions can damage a person's lungs and hinder their ability to function effectively, such as chronic obstructive pulmonary disease (COPD) including emphysema; scarring of the lungs; pulmonary fibrosis; cystic fibrosis; sarcoidosis; and pulmonary hypertension.2 The major limiting factor to the number of transplants performed is donor lung shortage.3 According to Organ Procurement Transplant Network data, approximately 130.5 deaths per 100,000 persons with severe lung disease occurred in 2014, with about 1400 patients with severe lung disease on the waiting list in the U.S.4.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Wednesday, April 17


News

Why Sprint, Bank of New York Mellon, and Mallinckrodt Slumped Today

BK MNK

Market participants pointed to persistent concerns like the state of the global economy and political issues in the U.S. and elsewhere around the world as weighing on positive sentiment, and a mixed earnings season thus far has held stocks back from reaching new record highs. That's the big reason why T-Mobile shares didn't sink nearly as much as Sprint today, and it reveals Sprint's vulnerability if it's forced to compete on its own in the U.S. wireless market. Bank of New York Mellon's stock dropped 9.5% after the banking institution reported its first-quarter financial results. BNY Mellon, which has been a recent favorite of Warren Buffett, does expect that setback to be only temporary, but that wasn't enough to reassure shareholders, who had hoped to see results more reminiscent of what some of the other top banks in the U.S. have reported so far this earnings season.

Read Full Details

Topics:
  • Business
  • Financial

Friday, April 12


News

Zacks Value Trader Highlights: G-III Apparel, General Motors, Legg Mason, Mallinckrodt and United Natural Foods

MNK LM +1 more MNK LM GM

Chicago, IL – April 12, 2019 – Zacks Value Trader is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. It provides great tips and tidbits for value investors including the key chapters on how to research a company through its financial statements, before buying. Zacks.com has a great classic value stock screen which applies the Zacks Ranks of #1 (Strong Buy) or #2 (Buy) along with P/E, PEG, P/Cash Flow, P/B, and P/S ratio.

Read Full Details

Topics:
  • Business
  • Financial
News

Mallinckrodt Completes Full Enrollment of its Phase 3 Clinical Trial for StrataGraft® Regenerative Skin Tissue

MNK

"This is an exciting milestone for StrataGraft, an investigational therapy that has the potential to revolutionize the standard of care for patients with severe burns," said Steven Romano, M.D., Executive Vice President and Chief Scientific Officer at Mallinckrodt. Donor site wounds are extremely painful, and can create risks of additional scarring and infection. As a result of achieving this important enrollment milestone, Mallinckrodt expects top-line data to be available by the end of 2019, following collection of follow-up data on the study's co-primary endpoints. Funding and technical support for the development of StrataGraft regenerative skin tissue is being provided by the Biomedical Advanced Research and Development Authority (BARDA), under the Assistant Secretary for Preparedness and Response, within the U.S. Department of Health and Human Services, under Project BioShield Contract No. Current standard of care for severe complex skin wounds involves the surgical harvesting of healthy skin tissue from an uninjured site on the patient and transplanting the autologous skin graft to the injury. While this process can be effective in providing closure of the original wound, it has significant limitations related to the donor site wounds created during surgical removal of autologous skin tissue for grafting.

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Financial

Thursday, April 11


News

Mallinckrodt and Washington University St. Louis Select First Collaborative Research Endeavor

MNK

STAINES-UPON-THAMES, United Kingdom, April 11, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK), a leading global specialty pharmaceutical company, today announced it has selected the first collaborative research endeavor with Washington University School of Medicine in St. Louis, a leader in medical research, teaching and patient care, under the multi-year partnership formed in 2018. This research aligns closely with Mallinckrodt's focus on meeting the needs of underserved patients, including those with certain underlying causes of chronic itch such as liver disease and kidney failure. "We are excited about this initial collaboration with Washington University School of Medicine under our research partnership, and look forward to seeing the results of applying the scientific and research expertise of both organizations to address this condition, often driven by underlying systemic causes," said Steven Romano, M.D., Executive Vice President and Chief Scientific Officer. Mallinckrodt plans to fund two types of grants – program and challenge – while also supporting direct collaboration with Washington University School of Medicine, guided by a joint steering committee with representatives from both parties.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Wednesday, April 10


News

Mallinckrodt's INOmax™ (Nitric Oxide) Gas, for Inhalation, Approved in Australia for Pulmonary Hypertension in Adults in Conjunction with Cardiovascular Surgery

MNK

INOmax nitric oxide is a vasodilator that opens (dilates) blood vessels, improving oxygen uptake and blood flow. Indications: INOmax, in conjunction with ventilatory support and other appropriate agents, is indicated:. For the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation. Special Warnings and Precautions: Do not use INOmax undiluted; INOmax must be diluted by the ventilator gas flow to a concentration not greater than 20ppm; use an approved nitric oxide gas delivery system provided by the sponsor that meets the criteria specified in the Dosage and Administration Section. Treatment with inhaled nitric oxide might aggravate cardiac insufficiency in a situation with left-to-right shunting; prior to the administration of nitric oxide, pulmonary artery catheterisation or echocardiographic examination of central haemodynamics is recommended.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Tuesday, April 09


News

Mallinckrodt (MNK) Dips More Than Broader Markets: What You Should Know

MNK

In the latest trading session, Mallinckrodt (MNK) closed at $23.58, marking a -1.13% move from the previous day. MNK will be looking to display strength as it nears its next earnings release, which is expected to be May 7, 2019. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988.

Read Full Details

Topics:
  • Business
  • Financial

Friday, April 05


News

Does Anyone Feel They Missed Out On Burlington Stores, Inc. (BURL), Mallinckrodt plc (MNK)?

MNK

Their shares witnessed a 18.22% increase from the 52-week low price of $132.35 they recorded on 2018-04-24. Even though it is still -15.22% behind the $180.27 high touched on 2018-11-14. Burlington Stores, Inc. (BURL) trade volume has decreased by -16.86% as around 1,159,797 shares were sold when compared with its 50-day average volume of traded shares which is 1,395,014. The shares of Mallinckrodt plc (NYSE:MNK) has increased by 3.24%, and now trading at $23.26 on the Wall Street in the intra-day deal, with their shares traded now around 1,290,197. This means that the stock price might likely increase by 31.86% from its current trading price.5 out of 15 Wall Street analysts which represents 33.33% rated the stock as a buy while the remaining 53.33% rated it as a hold, with 13.33% of analysts rating it as a sell.

Read Full Details

Topics:
  • Business
  • Financial
News

Mallinckrodt Announces Study Demonstrating Effectiveness of ECP Immunomodulation, as an adjunct to local standard therapy, in Treatment of Lung Transplant Patients with Bronchiolitis Obliterans Syndrome (BOS)

MNK

The study, led by Dr. Christian Joukhadar of J&P Medical Study Ltd., will be delivered in an oral presentation on Friday, 5 April, 2019 at the 39th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT) in Orlando, Florida, USA. "Mallinckrodt, a pioneer in the development and delivery of ECP immunomodulation, is pleased to see this study's evidence of the clinical efficacy in lung transplant recipients with BOS, and the notable cost savings this therapy can provide for hospitals," said Steven Romano, M.D., Executive Vice President and Chief Scientific Officer of Mallinckrodt. Mallinckrodt is the world's only provider of approved, fully-integrated systems for administering immunomodulatory therapy through ECP. THERAKOS Photopheresis is contraindicated in patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 mm3.

Read Full Details

Topics:
  • Business
  • Health
  • Financial